Skip to main content
SpringerLink
Log in

Ophthalmika

  • Chapter
Arzneiverordnungs-Report 2017

  • 2089 Accesses

Zusammenfassung

Die Indikationsgruppe der Ophthalmika umfasst Präparate, die in aller Regel lokal angewendet werden. Abbildung 38.1 gibt als Übersicht die wichtigsten Arzneimittelgruppen des Gesamtmarktes wieder. In den letzten beiden Jahrzehnten ist es dabei zu beträchtlichen Verschiebungen gekommen. Während früher fast zwei Drittel aller DDD auf Glaukommittel, Antikataraktika und Sympathomimetika entfielen, dominierten bis 2003 neben den Glaukommitteln vor allem die Filmbildner. Durch das GKV-Modernisierungsgesetz 2004 sind die Verordnungen zu Lasten der GKV vor allem bei den Filmbildnern, aber auch bei Sympathomimetika, Antiallergika, Vitaminen und Antikataraktika weitgehend weggefallen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 64.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • AGIS Investigators (2000): The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 130: 429–440

    Google Scholar 

  • American Academy of Ophthalmology Retina/Vitreous Panel, Preferred Practice Pattern Guidelines (2015): Age Related Macular degeneration. San Francisco, CA, 2015. Age-Related Macular Degeneration PPP - Updated 2015 (http://www.aao.org/preferred-practice-pattern/age-related-macular-degeneration-ppp-2015)

  • Aroney C, Fraser-Bell S, Lamoureux EL, Gillies MC, Lim LL, Fenwick EK (2016): Vision-Related Quality of Life Outcomes in the BEVORDEX Study: A clinical trial comparing Ozurdex sustained release dexamethasone intravitreal implant and bevacizumab treatment for diabetic macular edema. Invest Ophthalmol Vis Sci. 57: 5541–5546

    Google Scholar 

  • Behrens-Baumann W, Begall T (1993): Antiseptics versus antibiotics in the treatment of the experimental conjunctivitis caused by staphylococcus aureus. Ger J Ophthalmol 2: 409–411

    Google Scholar 

  • Berg K, Pedersen TR, Sandvik L, Bragadóttir R (2015): Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology 122: 146–152

    Google Scholar 

  • Bielory L (2002): Ocular allergy guidelines: a practical treatment algorithm. Drugs 62: 1611–1634

    Google Scholar 

  • Bielory L, Lien KW, Bigelsen S (2005): Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs 65: 215–228

    Google Scholar 

  • Biswas P, Sengupta S, Choudhary R, Home S, Paul A, Sinha S (2011): Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration. Indian J Ophthalmol 59: 191–196

    Google Scholar 

  • Bremond-Gignac D, Messaoud R, Lazreg S, Speeg-Schatz C, Renault D, Chiambaretta F (2015): A 3-day regimen with azithromycin 1.5% eyedrops for the treatment of purulent bacterial conjunctivitis in children: efficacy on clinical signs and impact on the burden of illness. Clin Ophthalmol 9: 725–732

    Google Scholar 

  • CATT Research Group (2011): Ranibizumab and bevacizumab for neovascular age-related macular degeneration. New Engl J Med 364: 1897–1908

    Google Scholar 

  • Chalita MR, Hofling-Lima AL, Paranhos A Jr, Schor P, Belfort R Jr (2004): Shifting trends in in vitro antibiotic susceptibilities for common ocular isolates during a period of 15 years. Am J Ophthalmol 137: 43–51

    Google Scholar 

  • Chaudhary V, Barbosa J, Lam WC, Mak M, Mavrikakis E, Mohaghegh P SM (2016): Ozurdex in age-related macular degeneration as adjunct to ranibizumab (The OARA Study). Can J Ophthalmol. 51: 302–305

    Google Scholar 

  • Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group (2012): Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119: 1388–1398

    Google Scholar 

  • Costagliola C, dell’Omo R, Romano MR, Rinaldi M, Zeppa L, Parmeggiani F (2009a): Pharmacotherapy of intraocular pressure: part I. Parasympathomimetic, sympathomimetic and sympatholytics. Expert Opin Pharmacother 10: 2663–2677

    Google Scholar 

  • Costagliola C, dell’Omo R, Romano MR, Rinaldi M, Zeppa L, Parmeggiani F (2009b): Pharmacotherapy of intraocular pressure - part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides. Expert Opin Pharmacother 10: 2859–2870

    Google Scholar 

  • Cvetkovic RS, Perry CM (2003): Brinzolamide: a review of its use in the management of primary open-angle glaucoma and ocular hypertension. Drugs Aging 20: 919–947

    Google Scholar 

  • Dakin HA, Wordsworth S, Rogers CA, Abangma G, Raftery J, Harding SP, Lotery AJ, Downes SM, Chakravarthy U, Reeves BC; IVAN Study Investigators (2014): Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial. BMJ Open 4: e005094

    Google Scholar 

  • Danesh-Meyer HV (2011): Neuroprotection in glaucoma: recent and future directions. Curr Opin Ophthalmol 22: 78–86

    Google Scholar 

  • Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW (2015): Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372: 1193–1203

    Google Scholar 

  • Dietlein TS, Hermann MM, Jordan JF (2009): Medikamentöse und chirurgische Therapie des Glaukoms. Dtsch Ärztebl Int 106: 597–606

    Google Scholar 

  • Donegan RK, Lieberman RL (2016): Discovery of molecular therapeutics for glaucoma: challenges, successes, and promising directions. J Med Chem 59: 788–809

    Google Scholar 

  • Doughty MJ, Glavin S (2009): Efficacy of different dry eye treatments with artificial tears or ocular lubricants: a systematic review. Ophthalmic Physiol Opt 29: 573–583

    Google Scholar 

  • Elshout M, van der Reis MI, Webers CA, Schouten JS (2014): The cost-utility of aflibercept for the treatment of agerelated macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters. Graefes Arch Clin Exp Ophthalmol 252: 1911–1920

    Google Scholar 

  • European Glaucoma Society: Terminology and guidelines for glaucoma. 4th Ed. (2014), DOGMA, Savona, Italien (http://www.eugs.org/eng/egs_guidelines_reg.asp?l=1)

  • Everett SL, Kowalski RP, Karenchak LM, Landsittel D, Day R, Gordon YL (1995): An in vitro comparison of the susceptibilities of bacterial isolates from patients with conjunctivitis and blepharitis to newer and established topical antibiotics. Cornea 14: 382–387

    Google Scholar 

  • Everitt HA, Little PS, Smith PW (2006): A randomised controlled trial of management strategies for acute infective conjunctivitis in general practice. Brit med J 333: 321

    Google Scholar 

  • Feiner L, Piltz-Seymour JR; Collaborative Initial Glaucoma Treatment Study (2003): Collaborative Initial Glaucoma Treatment Study: a summary of results to date. Curr Opin Ophthalmol 14: 106–111

    Google Scholar 

  • Garway-Heath DF, Crabb DP, Bunce C, Lascaratos G, Amalfitano F, Anand N, Azuara-Blanco A, Bourne RR, Broadway DC, Cunliffe IA, Diamond JP, Fraser SG, Ho TA, Martin KR, McNaught AI, Negi A, Patel K, Russell RA, Shah A, Spry PG, Suzuki K, White ET, Wormald RP, Xing W, Zeyen TG (2015): Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet 385: 1295–1304

    Google Scholar 

  • Garweg JG, Zandi S (2016): Retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex®) in its treatment. Graefes Arch Clin Exp Ophthalmol. 254: 1257–1265

    Google Scholar 

  • Gharbiya M, Giustolisi R, Allievi F, Fantozzi N, Mazzeo L, Scavella V, Gabrieli CB (2010): Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab – a randomized controlled trial. Am J Ophthalmol 149: 458–464.e1

    Google Scholar 

  • Giardini F, Grandi G, De Sanctis U, Eandi C, Machetta F, Pollino C, Grignolo FM (2011): In vitro susceptibility to different topical ophthalmic antibiotics of bacterial isolates from patients with conjunctivitis. Ocul Immunol Inflamm 19: 419–421

    Google Scholar 

  • Göbbels M, Gross D (1996): Klinische Studie der Wirksamkeit einer Dexpanthenol-haltigen künstlichen Tränenflüssigkeit (Siccaprotect) bei der Behandlung des trockenen Auges. Klin Monatsbl Augenheilkd 209: 84–88

    Google Scholar 

  • Goldberg I (2002): Should beta blockers be abandoned as initial monotherapy in chronic open angle glaucoma? The controversy. Br J Ophthalmol 86: 691–692

    Google Scholar 

  • Goldberg I, Crowston JG, Jasek MC, Stewart JA, Stewart WC; ADAPT Study Investigator Group (2012): Intraocular pressure-lowering efficacy of brinzolamide when added to travoprost/timolol fixed combination as adjunctive therapy. J Glaucoma 21: 55–59

    Google Scholar 

  • Granet DB, Dorfman M, Stroman D, Cockrum P (2008): A multicenter comparison of polymyxin B sulfate/trimethoprim ophthalmic solution and moxifloxacin in the speed of clinical efficacy for the treatment of bacterial conjunctivitis. J Pediatr Ophthalmol Strabismus 45: 340–349

    Google Scholar 

  • Grehn F (2008): Chirurgie des primären Offenwinkelglaukoms. Klin Monatsbl Augenheilkd 225: 30–38

    Google Scholar 

  • Greiner JV, Michaelson C, McWhirter CL, Shams NB (2002): Single dose of ketotifen fumarate .025% vs 2 weeks of cromolyn sodium 4% for allergic conjunctivitis. Adv Ther 19: 185–193

    Google Scholar 

  • Gunther JB, Altaweel MM (2009): Bevacizumab (avastin) for the treatment of ocular disease. Surv Ophthalmol 54: 372–400

    Google Scholar 

  • Haas W, Hesje CK, Sanfilippo CM, Morris TW (2011): High proportion of nontypeable Streptococcus pneumoniae isolates among sporadic, nonoutbreak cases of bacterial conjunctivitis. Curr Eye Res 36: 1078–1085

    Google Scholar 

  • Hanioglu-Kargi S, Basci N, Soysal H, Bozkurt A, Gursel E, Kayaalp O (1998): The penetration of ofloxacin into human aqueous humor given by various routes. Eur J Ophthalmol 8: 33–36

    Google Scholar 

  • Herkel U, Pfeiffer N (2001): Update on topical carbonic anydrase inhibitors. Curr Opin Ophthalmol 12: 88–93

    Google Scholar 

  • Hodge WG, Lachaine J, Steffensen I, Murray C, Barnes D, Foerster V, Ducruet T, Morrison A (2008): The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review. Br J Ophthalmol 92: 7–12

    Google Scholar 

  • Holz F, Martini B (2007): Pegaptanib. Intravitreale Injektion bei neovaskulärer altersabhängiger Makuladegeneration. Arzneimitteltherapie 25: 47–50

    Google Scholar 

  • Hwang DG, Schanzlin DJ, Rotberg MH, Foulks G, Raizman MB; Levofloxacin Bacterial Conjunctivitis Place-controlled

    Google Scholar 

  • Study Group (2003): A phase III, placebo controlled clinical trial of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis. Br J Ophthalmol 87: 1004–1009

    Google Scholar 

  • Isenberg SJ, Apt L, Valenton M, Del Signore M, Cubillan L, Labrador MA et al (2002): A controlled trial of povidoneiodine to treat infectious conjunctivitis in children. Am J Ophthalmol 134: 681–688

    Google Scholar 

  • Jackson WB, Low DE, Dattani D, Whitsitt PF, Leeder RG, Mac-Dougall R (2002): Treatment of acute bacterial conjunctivitis: 1% fusidic acid viscous drops vs. 0.3% tobramycin drops. Can J Ophthalmol 37: 228–237

    Google Scholar 

  • Jansen RM (2013): The off-label use of medication: the latest on the Avastin - Lucentis debacle. Med Law 32: 65–77

    Google Scholar 

  • Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP et al (2002): The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 120: 701–713

    Google Scholar 

  • Kass MA, Gordon MO, Gao F, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JK, Miller JP, Parrish RK, Wilson MR; Ocular Hypertension Treatment Study Group (2010): Delaying treatment of ocular hypertension: the ocular hypertension treatment study. Arch Ophthalmol 128: 276–287

    Google Scholar 

  • Katz LJ (1999): Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group. Am J Ophthalmol 127: 20–26

    Google Scholar 

  • Koss MJ, Eder M, Blumenkranz MS, Klauss V, Ta CN, de Kaspar HM (2007): Wirksamkeit neuer Fluorchinolone gegenüber der bakteriellen Normalflora der Bindehaut. Ophthalmologe 104: 21–27

    Google Scholar 

  • Kowalski RP, Kowalski TA, Shanks RM Romanowski EG, Karenchak LM, Mah FS (2013): In vitro comparison of combination and monotherapy for the empiric and optimal coverage of bacterial keratitis based on incidence of infection. Cornea 32: 830–834

    Google Scholar 

  • Krebs I, Schmetterer L, Boltz A, Told R, Vécsei-Marlovits V, Egger S, Schönherr U, Haas A, Ansari-Shahrezaei S, Binder S; MANTA Research Group (2013): A randomised doublemasked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol 97: 266–271

    Google Scholar 

  • Krupin T, Liebmann JM, Greenfield DS, Ritch R, Gardiner S; Low-Pressure Glaucoma Study Group (2011): A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. Am J Ophthalmol 151: 671–681

    Google Scholar 

  • Kuppermann BD, Goldstein M, Maturi RK, Pollack A, Singer M, Tufail A, Weinberger D, Li XY, Liu CC, Lou J, Whitcup SM; Ozurdex® ERIE Study Group (2015): Dexamethasone intravitreal implant as adjunctive therapy to ranibizumab in neovascular age-related macular degeneration: a multicenter randomized controlled trial. Ophthalmologica. 234: 40–54

    Google Scholar 

  • Lai DS, Lue KH, Hsieh JC, Lin KL, Lee HS (2002): The comparison of the efficacy and safety of cetirizine, oxatomide, ketotifen, and a placebo for the treatment of childhood perennial allergic rhinitis. Ann Allergy Asthma Immunol 89: 589–598

    Google Scholar 

  • Lamoureux EL, Mcintosh R, Constantinou M, Fenwick EK, Xie J, Casson R, Finkelstein E, Goldberg I, Healey P, Thomas R, Ang GS, Pesudovs K, Crowston J (2015): Comparing the effectiveness of selective laser trabeculoplasty with topical medication as initial treatment (the Glaucoma Initial Treatment Study): study protocol for a randomised controlled trial. Trials 16: 406

    Google Scholar 

  • Leonardi A, Van Setten G, Amrane M, Ismail D, Garrigue JS, Figueiredo FC, Baudouin C (2016): Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur J Ophthalmol. 26: 287–296

    Google Scholar 

  • Leung VC, Jin YP, Hatch W, Mammo Z, Trope GE, Buys YM, Macrae WG (2015): The relationship between sociodemographic factors and persistence with topical glaucoma medications. J Glaucoma 24: 69–76

    Google Scholar 

  • Lynch SS, Cheng CM (2007): Bevacizumab for neovascular ocular diseases. Ann Pharmacother. 41: 614–625

    Google Scholar 

  • Maguire MG, Daniel E, Shah AR, Grunwald JE, Hagstrom SA, Avery RL, Huang J, Martin RW, Roth DB, Castellarin AA, Bakri SJ, Fine SL, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT Research Group) (2013): Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials. Ophthalmology 120: 2035–2041

    Google Scholar 

  • Mantadakis E, Maraki S, Michailidis L, Gitti Z, Pallikaris IG, Samonis G (2013): Antimicrobial susceptibility of Grampositive cocci isolated from patients with conjunctivitis and keratitis in Crete, Greece. J Microbiol Immunol Infect 46: 41–47

    Google Scholar 

  • Messmer EM (2012): Bakterielle Konjunktivitis - Update zu Diagnose und Therapie. Klin Monbl Augenheilkd 229: 529–533

    Google Scholar 

  • Musch DC, Gillespie BW, Niziol LM, Lichter PR, Varma R; CIGTS Study Group (2011): Intraocular pressure control and long-term visual field loss in the Collaborative Initial Glaucoma Treatment Study. Ophthalmology 118: 1766–1773

    Google Scholar 

  • Nesher R; Israel Glaucoma Screening Group (2014): Prevalence of increased intraocular pressure and optic disk cupping: multicenter glaucoma screening in Israel during the 2009 and 2010 World Glaucoma Weeks. Isr Med Assoc J 16: 483–486

    Google Scholar 

  • Noble S, McTavish D (1995): Levocabastine. An update of its pharmacology, clinical efficacy and tolerability in the topical treatment of allergic rhinitis and conjunctivitis. Drugs 50: 1032–1049

    Google Scholar 

  • Nordlund JR, Pasquale LR, Robin AL et al (1995): The cardio vascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine. Arch Ophthalmol 113: 77–83

    Google Scholar 

  • O’Brien TP, Maguire MG, Fink NE, Alfonso E, McDonnell P (1995): Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis. Arch Ophthalmol 113: 1257–1265

    Google Scholar 

  • Orden Martinez B, Martinez Ruiz R, Millan Perez R (2004): Bakterielle Konjunktivitis: Prävalenz von Pathogenen und ihre Antibiotikaresistenz [Artikel auf Spanisch]. An Pediatr (Barc) 61: 32–36

    Google Scholar 

  • Parrish RK, Palmberg P, Sheu WP and the XLT Study Group (2003): A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 135: 688–703

    Google Scholar 

  • Parrish RK, Feuer WJ, Schiffman JC, Lichter PR, Musch DC; CIGTS Optic Disc Study Group (2009): Five-year follow-up optic disc findings of the Collaborative Initial Glaucoma Treatment Study. Am J Ophthalmol 147: 717–724

    Google Scholar 

  • Perry CM, McGavin JK, Culy CR, Ibbotson T (2003): Latanoprost: an update of its use in glaucoma and ocular hypertension. Drugs Aging 20: 597–630

    Google Scholar 

  • Pfeiffer N (2005): Ergebnisse der “Ocular hypertension treatment study” (OHTS) Ophthalmologe 102: 230–234

    Google Scholar 

  • Pfeiffer N, TATS (Travatan Adjunctive Treatment Study) group (2011): Timolol versus brinzolamide added to travoprost in glaucoma or ocular hypertension. Graefes Arch Clin Exp Ophthalmol 249: 1065–1071

    Google Scholar 

  • Prum BE Jr, Rosenberg LF, Gedde SJ, Mansberger SL, Stein JD, Moroi SE, Herndon LW Jr, Lim MC, Williams RD (2016): Primary open-angle glaucoma preferred practice pattern guidelines. Ophthalmology. 123: P41–P111

    Google Scholar 

  • Quigley HA (1996): Number of people with glaucoma worldwide. Brit J Ophthalmol 80: 389–393

    Google Scholar 

  • Rachwalik D, Pleyer U (2015): Bakterielle Keratitis. Klin Monbl Augenheilkd 232: 738–744

    Google Scholar 

  • Ravinet E, Mermoud A, Brignoli R (2003): Four years later: a clinical update on latanoprost. Eur J Ophthalmol 13: 162–175

    Google Scholar 

  • Ray KJ, Srinivasan M, Mascarenhas J, Rajaraman R, Ravindran M, Glidden DV, Oldenburg CE, Sun CQ, Zegans ME, McLeod SD, Acharya NR, Lietman TM (2014): Early add ition of topical corticosteroids in the treatment of bacterial keratitis. JAMA Ophthalmol 132: 737–741

    Google Scholar 

  • Rietveld RP, ter Riet G, Bindels PJ, Sloos JH, van Weert HC (2004): Predicting bacterial cause in infectious conjunctivitis: cohort study on informativeness of combinations of signs and symptoms. Brit med J 329: 206–210

    Google Scholar 

  • Rose P (2007): Management strategies for acute infective conjunctivitis in primary care: a systematic review. Expert Opin Pharmacother 8: 1903–1921

    Google Scholar 

  • Rosenfeld PJ (2011): Bevacizumab versus Ranibizumab –The Verdict. New Engl J Med 364: 1966–1967

    Google Scholar 

  • Sabel BA, Gudlin J (2014): Vision restoration training for glaucoma: a randomized clinical trial. JAMA Ophthalmol 132: 381–389

    Google Scholar 

  • Sarwar S, Clearfield E, Soliman MK, Sadiq MA, Baldwin AJ, Hanout M, Agarwal A, Sepah YJ, Do DV, Nguyen QD (2016): Aflibercept for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2016: CD011346

    Google Scholar 

  • Schachar RA, Raber S, Courtney R, Zhang M (2011): A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension. Curr Eye Res 36: 809–817

    Google Scholar 

  • Schalnus R (2003): Topical nonsteroidal anti-inflammatory therapy in ophthalmology. Ophthalmologica 217: 89–98

    Google Scholar 

  • Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, Ho AC, Ogura Y, Simader C, Jaffe GJ, Slakter JS, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Sowade O, Zeitz O, Norenberg C, Sandbrink R, Heier JS (2014): Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninetysix-week results of the VIEW studies. Ophthalmology 121: 193–201

    Google Scholar 

  • Schwab IR, Friedlaender M, McCulley J, Lichtenstein SJ, Moran CT; Levofloxacin Bacterial Conjunctivitis Active Control Study Group (2003): A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis. Ophthalmology 110: 457–465

    Google Scholar 

  • Sena DF, Ramchand K, Lindsley K (2010): Neuroprotection for treatment of glaucoma in adults. Cochrane Database Syst Rev. 2010: CD006539

    Google Scholar 

  • Sheikh A, Hurwitz B, van Schayck CP, McLean S, Nurmatov U (2012): Antibiotics versus placebo for acute bacterial conjunctivitis. Cochrane Database Syst Rev. 2012: CD001211

    Google Scholar 

  • Solomon SD, Lindsley KB, Krzystolik MG, Vedula SS, Hawkins BS (2016): Intravitreal bevacizumab versus ranibizumab for treatment of neovascular age-related macular degeneration: findings from a Cochrane systematic review. Ophthalmology 123: 70–77

    Google Scholar 

  • Sorensen SJ, Abel SR (1996): Comparison of the ocular betablockers. Ann Pharmacother 30: 43–54

    Google Scholar 

  • Srinivasan M, Mascarenhas J, Rajaraman R, Ravindran M, Lalitha P, Glidden DV, Ray KJ, Hong KC, Oldenburg CE, Lee SM, Zegans ME, McLeod SD, Lietman TM, Acharya NR; Steroids for Corneal Ulcers Trial Group (2012): Corticosteroids for bacterial keratitis: the Steroids for Corneal Ulcers Trial (SCUT). Arch Ophthalmol. 130: 143–150

    Google Scholar 

  • Srinivasan M, Mascarenhas J, Rajaraman R, Ravindran M, Lalitha P, O’Brien KS, Glidden DV, Ray KJ, Oldenburg CE, Zegans ME, Whitcher JP, McLeod SD, Porco TC, Lietman TM, Acharya NR; Steroids for Corneal Ulcers Trial Group (2014): The steroids for corneal ulcers trial (SCUT): secondary 12-month clinical outcomes of a randomized controlled trial. Am J Ophthalmol. 157: 327–333.e3

    Google Scholar 

  • Subramanian ML, Ness S, Abedi G, Ahmed E, Daly M, Feinberg E, Bhatia S, Patel P, Nguyen M, Houranieh A (2009): Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective doublemasked, randomized clinical trial. Am J Ophthalmol 148: 875–882.e1

    Google Scholar 

  • Tamm ER, Schmetterer L, Grehn F (2013): Status and perspectives of neuroprotective therapies in glaucoma: the European Glaucoma Society White Paper. Cell Tissue Res 353: 347–354

    Google Scholar 

  • The Comparison of Age-Related Macular Degeneration Treatments Trials (2016): Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119: 1388–1398

    Google Scholar 

  • Uusitalo H, Pillunat LE, Ropo A (2010): Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study. Acta Ophthalmol 88: 12–19

    Google Scholar 

  • van de Velde S, De Groef L, Stalmans I, Moons L, Van Hove I (2015): Towards axonal regeneration and neuroprotection in glaucoma: Rho kinase inhibitors as promising therapeutics. Prog Neurobiol. 131: 105–19

    Google Scholar 

  • van der Valk R, Webers CA, Schouten JS, Zeegers MP, Hendrikse F, Prins MH (2005): Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a metaanalysis of randomized clinical trials. Ophthalmology 112: 1177–1185

    Google Scholar 

  • Vickerstaff V, Ambler G, Bunce C, Xing W, Gazzard G; LiGHT Trial Study Group (2015): Statistical analysis plan for the laser-1st versus drops-1st for glaucoma and ocular hypertension trial (LiGHT): a multi-centre randomised controlled trial. Trials 16: 517

    Google Scholar 

  • Wand M, Gilbert CM, Liesegang TJ (1999): Latanoprost and herpes simplex keratitis. Am J Ophthalmol 127: 602–604

    Google Scholar 

  • Watson PG, Barnett MF, Parker V, Haybittle J (2001): A 7 year prospective comparative study of three topical beta blockers in the management of primary open angle glaucoma. Br J Ophthalmol 85: 962–968

    Google Scholar 

  • Webers CA, Beckers HJ, Nuijts RM, Schouten JS (2008): Pharmacological management of primary open-angle glaucoma: second-line options and beyond. Drugs Aging 25: 729–759

    Google Scholar 

  • Weinreb RN, Khaw PT (2004): Primary open-angle glaucoma. Lancet 363: 1711–1720

    Google Scholar 

  • Whitson JT (2007): Glaucoma: a review of adjunctive therapy and new management strategies. Expert Opin Pharmacother 8: 3237–3249

    Google Scholar 

  • Wright M, Butt Z, McIlwaine G, Fleck B (1997): Comparison of the efficacy of diclofenac and betamethasone following strabismus surgery. Brit J Ophthalmol 81: 299–301

    Google Scholar 

  • Yildirim N, Sahin A, Gultekin S (2008): The effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-angle glaucoma. J Glaucoma 17: 36–39

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Max-Delbrück-Centrum für Molekulare Medizin, Robert-Rössle-Straße 10, 13125, Berlin-Buch, Deutschland

    Martin J. Lohse

Authors
  1. Martin J. Lohse
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin J. Lohse .

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg, Deutschland

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln, Deutschland

    Dieter Paffrath

  3. Arzneimittelkommission der deutschen Ärzteschaft, Herbert-Lewin-Platz 1, 10623, Berlin, Deutschland

    Wolf-Dieter Ludwig

  4. Wissenschaftliches Institut der AOK (WIdO), Rosenthaler Straße 31, 10178, Berlin, Deutschland

    Jürgen Klauber

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer-Verlag GmbH Germany

About this chapter

Cite this chapter

Lohse, M.J. (2017). Ophthalmika. In: Schwabe, U., Paffrath, D., Ludwig, WD., Klauber, J. (eds) Arzneiverordnungs-Report 2017. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-54630-7_38

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-54630-7_38

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-54629-1

  • Online ISBN: 978-3-662-54630-7

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation